June 2021

Miromatrix Medical Closes $50M IPO

United States - Delaware | United States - Minnesota

Miromatrix Medical, a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, closed its $50 million initial public offering (IPO) of 5,520,000 shares of its common stock at a public offering price of $9 per share, which began trading on the Nasdaq Stock Market on June 24, 2021 under the ticker symbol MIRO. Faegre Drinker represented Miromatrix Medical in the IPO, with professionals from the corporate, executive compensation, corporate governance, FDA and health care regulatory, tax, Delaware corporate and capital markets practices resident in the Minneapolis, Philadelphia, Washington, D.C., Indianapolis, Boulder, New York and Wilmington offices advising on the transaction.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.